O. Ritter

Prof. Dr. O. Ritter


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2025 in JCI Insight
Verified
Journal Article
Open access
BSBenjamin Sasko
Benjamin Sasko
LSLinda Scharow
Linda Scharow
RMRhea Mueller
Rhea Mueller
MJMonique Jaensch
Monique Jaensch
Werner DammermannWerner Dammermann
Werner Dammermann
NPNikolaos Pagonas
Nikolaos Pagonas
RESULTS. Participants with CAD ( n = 723) had 12% higher mean relative levels of nHDL ox compared with those with invasively excluded CAD ( n = 502, P < 0.001). Patients presenting with symptoms of an ACS had the highest nHDL ox values when compared with the elective cohort (median 1.35, IQR 0.97 to 1.85, P < 0.001). In multivariate analysis adjusted for age, sex, body mass index, and hypertension, nHDL ox was a strong independent predictor of ACS ( P < 0.001) but not of CAD ( P > 0.05).CONCLUSION. HDL antioxidant function is reduced in patients with CAD. nHDL ox is strongly associated with ACS. TRIAL REGISTRATION. German Clinical Trials Register DRKS00014037. FUNDING. Brandenburg Medical School Theodor Fontane, the BIOX Stiftung, and NIH grants R01AG059501 and R03AG059462. BACKGROUND. High-density lipoprotein (HDL) function rather than its concentration plays an important role in the pathogenesis of coronary artery disease (CAD). The aim of the present study was to determine whether reduced antioxidant function of HDL is associated with the presence of a stable CAD or acute coronary syndrome (ACS).METHODS. HDL function was measured in 2 cohorts: 1225 patients admitted electively for coronary angiography and 196 patients with ACS. A validated cell-free biochemical assay was used to determine reduced HDL antioxidant function, as assessed by increased HDL-lipid peroxide content (HDL ox ), which was normalized by HDL-C levels and the mean value of a pooled serum control from healthy participants (nHDL ox ; unitless). Results are expressed as median with interquartile range (IQR).

28 April 2025 in Cells
Verified
Journal Article
Open access
PDF file
TFTobias Fischer
Tobias Fischer
SGSina Gredy
Sina Gredy
NSNadine Scheel
Nadine Scheel
PBPeter M. Benz
Peter M. Benz
BFBenjamin Fissler
Benjamin Fissler
KSKai Schuh
Kai Schuh
So far, the molecular functions of the angiotensin-type-2 receptor (AT2) interacting protein (ATIP1) have remained unclear, although expression studies have revealed high levels of ATIP1 in the heart. To unravel its physiological function, we investigated ATIP1-KO mice. They develop a spontaneous cardiac hypertrophy with a significantly increased heart/bodyweight ratio, enlarged cardiomyocyte diameters, and augmented myocardial fibrosis. Hemodynamic measurements revealed an increased ejection fraction (EF) in untreated ATIP1-KO mice, and reduced end-systolic and end-diastolic volumes (ESV and EDV), which, in sum, reflect a compensated concentric cardiac hypertrophy. Importantly, no significant differences in blood pressure (BP) were observed. Chronic angiotensin II (AngII) infusion resulted in increases in BP and EF in ATIP1-KO and WT mice. Reductions in ESV and EDV occurred in both ATIP1-KO and WT but to a lesser extent in ATIP1-KOs. Isolated cardiomyocytes exhibited a significantly increased contractility in ATIP1-KO and accelerated Ca2+ decay. AngII treatment resulted in increased fractional shortening in WT but decreased shortening in ATIP1-KO, accompanied by accelerated cell relaxation in WT but absent effects on relaxation in ATIP1-KO cells. The AT2 agonist CGP42112A increased shortening in WT cardiomyocytes but, again, did not affect shortening in ATIP1-KO cells. Relaxation was accelerated by CGP42112A in WT but was unaffected in ATIP1-KO cells. We show that ATIP1 deficiency results in spontaneous cardiac hypertrophy in vivo and that ATIP1 is a downstream signal in the AT2 pathway regulating cell contractility. We hypothesize that the latter effect is because of a disinhibition of the AT1 pathway by impaired AT2 signaling.

31 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TFTobias Fischer
Tobias Fischer
SGSina Gredy
Sina Gredy
NSNadine Scheel
Nadine Scheel
PBPeter M. Benz
Peter M. Benz
BFBenjamin Fissler
Benjamin Fissler
KSKai Schuh
Kai Schuh
So far, the molecular functions of the angiotensin type-2 receptor (AT2) interacting protein (ATIP1) remained unclear although expression studies revealed high levels of ATIP1 in the heart. To unravel its physiological function, we investigated ATIP1-KO mice. They develop a spontaneous cardiac hypertrophy with significantly increased heart/body weight ratio, enlarged cardiomyocyte diameters, and augmented myocardial fibrosis. Hemodynamic measurements revealed an increased ejection fraction (EF) in untreated ATIP1-KO mice, and reduced end-systolic and end-diastolic volumes (ESV and EDV), which in sum reflects a compensated concentric cardiac hypertrophy. Importantly, no significant differences in blood pressure (BP) were observed. Chronic angiotensin II (AngII) infusion resulted in an increase of BP and EF in ATIP1-KO and WT mice. Reduction of ESV and EDV occurred both in ATIP1-KO and WT, but to a lesser extent in ATIP1-KOs. Isolated cardiomyocytes exhibited a significantly increased contractility in ATIP1-KO and accelerated Ca2+ decay. AngII treatment resulted in increased fractional shortening in WT but decreased shortening in ATIP1-KO, accompanied by accelerated cell relaxation in WT but absent effects on relaxation in ATIP1-KO cells. The AT2-agonist CGP42112A increased shortening in WT cardiomyocytes but again did not affect shortening in ATIP1-KO cells. Relaxation was accelerated by CGP42112A in WT, but unaffected in ATIP1-KO cells. We here show that ATIP1-deficiency results in spontaneous cardiac hypertrophy in vivo and that ATIP1 is a downstream signal in the AT2-pathway regulating cell contractility. We hypothesize that the latter effect is due to a disinhibition of the AT1-pathway by impaired AT2-signaling.

21 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
BSBenjamin Sasko
Benjamin Sasko
TSTonghuan Shi
Tonghuan Shi
MCMartin Christ
Martin Christ
ORO. Ritter
O. Ritter
SKSawa Kostin
Sawa Kostin
NPNikolaos Pagonas
Nikolaos Pagonas
Background: Obesity, commonly defined by body mass index (BMI), promotes cardiovascular disease through chronic inflammation and oxidative stress, which impair high-density lipoprotein (HDL) function and favor oxidative modification. Oxidized HDL (HDLox) may link adiposity to cardiovascular risk. However, the association between BMI and HDLox across the adiposity spectrum remains unclear. We therefore examined this relationship in a Coronary-Suspected Cohort. Methods: This study included 1,227 consecutive patients undergoing elective coronary angiography. Participants were stratified into five predefined BMI categories. HDLox was quantified using a validated fluorometric assay assessing HDL lipid peroxide content. Associations between BMI and HDLox were analyzed using univariable and multivariable linear regression across the full BMI range and within a restricted BMI interval (15–35 kg/m²). Results: HDLox levels were significantly higher in overweight and obese individuals compared with normal-weight participants (p = 0.002 and p < 0.001). HDLox increased from normal weight to obesity class I (BMI 30–34.9 kg/m²) and plateaued at higher BMI levels, indicating a non-linear relationship. In the overall cohort, BMI showed a weak but significant association with HDLox (β = 0.064, p = 0.024). Within the restricted BMI interval, the association was more pronounced (β = 0.158, p < 0.001). In multivariable models, BMI, high-sensitivity C-reactive protein, and male sex remained independently associated with HDLox, whereas traditional cardiovascular risk factors were not. Conclusions: HDL oxidation increases early during weight gain and may represent a functional marker linking adiposity-related inflammation and oxidative stress to cardiovascular vulnerability.

Verified
Journal Article
Open access
PDF file
BSBenjamin Sasko
Benjamin Sasko
TSTonghuan Shi
Tonghuan Shi
MCMartin Christ
Martin Christ
ORO. Ritter
O. Ritter
SKSawa Kostin
Sawa Kostin
NPNikolaos Pagonas
Nikolaos Pagonas
Obesity, commonly defined by body mass index (BMI), promotes cardiovascular disease through chronic inflammation and oxidative stress, which impair high-density lipoprotein (HDL) function and favor oxidative modification. Oxidized HDL (HDLox) may link adiposity to cardiovascular risk. However, the association between BMI and HDLox across the adiposity spectrum remains unclear. We therefore examined this relationship in a Coronary-Suspected Cohort. This study included 1227 consecutive patients undergoing elective coronary angiography. Participants were stratified into five predefined BMI categories. HDLox was quantified using a validated fluorometric assay assessing HDL lipid peroxide content. Associations between BMI and HDLox were analyzed using univariable and multivariable linear regression across the full BMI range and within a restricted BMI interval (15–35 kg/m2). HDLox levels were significantly higher in overweight and obese individuals compared with normal-weight participants (p = 0.002 and p < 0.001). HDLox increased from normal weight to obesity class I (BMI 30–34.9 kg/m2) and plateaued at higher BMI levels, indicating a non-linear relationship. In the overall cohort, BMI showed a weak but significant association with HDLox (β = 0.064, p = 0.024). Within the restricted BMI interval, the association was more pronounced (β = 0.158, p < 0.001). In multivariable models, BMI, high-sensitivity C-reactive protein, and male sex remained independently associated with HDLox, whereas traditional cardiovascular risk factors were not. HDL oxidation increases early during weight gain and may represent a functional marker linking adiposity-related inflammation and oxidative stress to cardiovascular vulnerability.

19 February 2026 in JCI Insight
Verified
Journal Article
Open access
PDF file
JTJohanna Tennigkeit
Johanna Tennigkeit
MWMaurice Wiegelmann
Maurice Wiegelmann
CMChiara Massa
Chiara Massa
JLJonas Lübcke
Jonas Lübcke
Werner DammermannWerner Dammermann
Werner Dammermann
GSGregor Sachse
Gregor Sachse
A blood marker called GDF15, measured before ablation, can predict arrhythmia recurrence within 24 hours, suggesting immune reactions influence healing and treatment success.